Opaleye Management’s Protagonist Therapeutics PTGX Stock Holding History

Opaleye Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.5M	Sell	100,000 -5,000	-5%	-$443K	1.39%	21
2025 Q4	$9.17M	Hold	105,000	–	–	1.21%	20
2025 Q3	$6.98M	Hold	105,000	–	–	0.99%	23
2025 Q2	$5.8M	Hold	105,000	–	–	1.17%	21
2025 Q1	$5.08M	Hold	105,000	–	–	1.13%	16
2024 Q4	$4.05M	Hold	105,000	–	–	0.71%	27
2024 Q3	$4.72M	Hold	105,000	–	–	0.79%	25
2024 Q2	$3.64M	Sell	105,000 -7,700	-7%	-$226K	0.83%	33
2024 Q1	$3.26M	Hold	112,700	–	–	0.71%	34
2023 Q4	$2.58M	Buy	+112,700	New	+$1.97M	0.69%	36
2022 Q2	–	Sell	-251,500	Closed	-$5.96M	–	51
2022 Q1	$5.96M	Sell	251,500 -90,500	-26%	-$2.55M	1.85%	18
2021 Q4	$11.7M	Buy	342,000 +11,778	+4%	+$372K	2.48%	13
2021 Q3	$5.85M	Hold	330,222	–	–	1.09%	28
2021 Q2	$14.8M	Buy	330,222 +33,222	+11%	+$1.1M	2.46%	13
2021 Q1	$7.69M	Buy	297,000 +37,000	+14%	+$936K	1.13%	28
2020 Q4	$7.02M	Buy	+260,000	New	+$5.6M	0.92%	28

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Opaleye Management's PTGX Position: Q1 2026 in Review

Opaleye Management reduced its Protagonist Therapeutics (PTGX) stake by 4.8% in Q1 2026, selling an estimated $443K and leaving 100,000 shares worth $10.5M. The position accounts for 1.39% of the portfolio, ranked #21.

Opaleye Management first reported a position in PTGX in Q4 2020 and has held it in 16 quarters since. The position peaked at $14.8M in Q2 2021. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

Opaleye Management held 100,000 shares of Protagonist Therapeutics worth $10.5M as of Q1 2026.
Opaleye Management sold 5,000 Protagonist Therapeutics shares in Q1 2026, an estimated $443K.
Protagonist Therapeutics made up 1.39% of Opaleye Management's portfolio in Q1 2026, its #21 holding.
Opaleye Management first reported a position in Protagonist Therapeutics in Q4 2020 and has held it in 16 quarters since.
Opaleye Management's Protagonist Therapeutics position peaked at $14.8M in Q2 2021.
317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Opaleye Management's 13F filing for Q1 2026, filed 15 May 2026.